|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003873,
umls-concept:C0008976,
umls-concept:C0025677,
umls-concept:C0030705,
umls-concept:C0205412,
umls-concept:C0243127,
umls-concept:C0439831,
umls-concept:C0443331,
umls-concept:C0545661,
umls-concept:C0597357,
umls-concept:C1274040,
umls-concept:C1609165,
umls-concept:C1623145,
umls-concept:C1999216,
umls-concept:C2745888
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-1-13
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
To investigate the effects of tocilizumab (TCZ) added to a stable dosage of methotrexate (MTX) on biochemical markers of bone and cartilage metabolism in patients in the multicenter double-blind, placebo-controlled OPTION (Tocilizumab Pivotal Trial in Methotrexate Inadequate Responders) study who have moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to MTX.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen Type II,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 3,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Osteocalcin,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Procollagen,
http://linkedlifedata.com/resource/pubmed/chemical/collagen type I trimeric...,
http://linkedlifedata.com/resource/pubmed/chemical/procollagen Type I N-terminal...,
http://linkedlifedata.com/resource/pubmed/chemical/procollagen type IIA...,
http://linkedlifedata.com/resource/pubmed/chemical/tocilizumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
33-43
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20039425-Antibodies, Monoclonal,
pubmed-meshheading:20039425-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20039425-Arthritis, Rheumatoid,
pubmed-meshheading:20039425-Biological Markers,
pubmed-meshheading:20039425-Cartilage, Articular,
pubmed-meshheading:20039425-Chondrogenesis,
pubmed-meshheading:20039425-Collagen Type I,
pubmed-meshheading:20039425-Collagen Type II,
pubmed-meshheading:20039425-Double-Blind Method,
pubmed-meshheading:20039425-Drug Therapy, Combination,
pubmed-meshheading:20039425-Drug Tolerance,
pubmed-meshheading:20039425-Female,
pubmed-meshheading:20039425-Health Status,
pubmed-meshheading:20039425-Humans,
pubmed-meshheading:20039425-Male,
pubmed-meshheading:20039425-Matrix Metalloproteinase 3,
pubmed-meshheading:20039425-Methotrexate,
pubmed-meshheading:20039425-Middle Aged,
pubmed-meshheading:20039425-Osteocalcin,
pubmed-meshheading:20039425-Osteogenesis,
pubmed-meshheading:20039425-Peptide Fragments,
pubmed-meshheading:20039425-Peptides,
pubmed-meshheading:20039425-Procollagen
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
|
|
pubmed:affiliation |
INSERM Unit 664, Lyon, France. patrickgarnero@free.fr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
